Goldman Sachs
ESPR

Goldman Sachs’s Esperion Therapeutics ESPR Stock Holding History

Goldman Sachs’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-30,000
Closed -$946K – 5270
2020
Q1 		$946K Buy
+30,000
New +$1.58M ﹤0.01% 3802
2018
Q1 		– Sell
-2,200
Closed -$145K – 6006
2017
Q4 		$145K Sell
2,200
-16,300
-88% -$878K ﹤0.01% 5572
2017
Q3 		$927K Sell
18,500
-20,300
-52% -$979K ﹤0.01% 4639
2017
Q2 		$1.8M Buy
38,800
+12,500
+48% +$460K ﹤0.01% 3926
2017
Q1 		$929K Buy
26,300
+12,700
+93% +$291K ﹤0.01% 4448
2016
Q4 		$170K Buy
13,600
+1,300
+11% +$15.5K ﹤0.01% 5873
2016
Q3 		$170K Buy
12,300
+7,600
+162% +$86.1K ﹤0.01% 5925
2016
Q2 		$46K Sell
4,700
-40,600
-90% -$673K ﹤0.01% 6454
2016
Q1 		$766K Sell
45,300
-8,000
-15% -$129K ﹤0.01% 4323
2015
Q4 		$1.19M Sell
53,300
-44,800
-46% -$1.13M ﹤0.01% 4130
2015
Q3 		$2.31M Sell
98,100
-373,500
-79% -$23.4M ﹤0.01% 3638
2015
Q2 		$38.6M Buy
471,600
+470,500
+42,773% +$46.1M 0.01% 1303
2015
Q1 		$102K Buy
+1,100
New +$71K ﹤0.01% 6416

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs's ESPR Position: Q2 2026 in Review

Goldman Sachs increased its Esperion Therapeutics (ESPR) stake by 331% in Q2 2026, buying an estimated $22.3M and bringing the position to 10,380,646 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Goldman Sachs first reported a position in ESPR in Q3 2013 and has held it in 49 quarters since. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Goldman Sachs held 10,380,646 shares of Esperion Therapeutics worth $32.8M as of Q2 2026.
  • Goldman Sachs bought 7,970,192 Esperion Therapeutics shares in Q2 2026, an estimated $22.3M.
  • Esperion Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2175 holding.
  • Goldman Sachs first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 49 quarters since.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.